InfraReDx Inc. is on a roll this fall. The Burlington, Mass.-based medical device maker won 510(k) clearance from the Food & Drug Administration in early September for its LipiScan IVUS coronary imaging system and pulled in $21 million in an equity offering a month later, which it plans to use to fund the U.S. rollout of the device.
The LipiScan IVUS uses both so-called “near-infrared” spectroscopy and intravascular ultrasound technology to give cardiologists a grayscale IVUS image of a coronary artery, along with a map of lipid core coronary plaques within a blood vessel.
Earlier this year, MassDevice.com co-founder and publisher Brian Johnson sat down with InfraReDx co-founder, CEO and chief medical officer Dr. James Muller to find out about the company’s road to commercialization.
Muller touched on the challenges of convincing investors that the technology was a good bet, the engineering that went into developing the device and how innovative technologies like his can help reduce the cost of healthcare.
Click here to listen to the podcast for free. You can also download an MP3 of the interview by right-clicking.